The news that Eli Lilly's experimental anti-clotting drug Prasrugel was linked with a higher risk of fatal bleeding has converted a large group of analysts into disbelievers in the company's stock price. Specifically, Barron's is quoting a slate of analysts skeptical that the drug can be approved as is and worried by the absence of any other potential blockbuster in the Lilly pipeline. Lilly has maintained a much more optimistic attitude, noting that its recent crop of data [1] indicates that the drug demonstrated efficacy in reducing heart attacks and strokes with fewer major incidents than Plavix. The analysts are betting that the FDA will want more studies--and that will take considerably more time than planned.
- read the report [2] from Barron's
Related Articles:
Lilly drug outperforms Plavix, but there's a catch. Report [1]
Lilly suspends dosing in crucial drug trial. Report [3]
Lilly pits drug against Plavix in trial. Report [4]
Links:
[1] http://www.fiercebiotech.com/story/lilly-drug-outperforms-plavix-theres-catch/2007-11-05
[2] http://seekingalpha.com/article/54606-eli-lilly-may-keep-bleeding-barron-s
[3] http://www.fiercebiotech.com/story/lilly-suspends-dosing-crucial-drug-trial/2007-10-25
[4] http://www.fiercebiotech.com/story/lilly-pits-experimental-drug-against-plavix-in-head-to-head-trial/2005-11-02